Importantly, existing studies have shown that both GLP-1 receptor agonists and SGLT2 inhibitors can significantly reduce all-cause mortality and cardiovascular events in patients with type 2 diabetes by lowering blood pressure and improving cardiovascular health, with observational data further suggesting that combination therapy offers greater advantages in reducing MACE, heart failure hospitalizations, and all-cause mortality (44–46). This evidence concerns the gene SLC5A2 and heart failure.